Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Taste-Based Influenza Test Could Replace Nasal Swabs with Chewing Gum

By HospiMedica International staff writers
Posted on 07 Oct 2025

Influenza is one of the most dangerous infectious diseases worldwide, claiming around half a million lives each year. More...

What makes it particularly insidious is that flu viruses are contagious even before the first symptoms appear. Yet, diagnostic options are often expensive, complicated to use, and unavailable in many poorer regions. Now, a new, very simple self-test in the form of chewing gum or a lollipop could detect infection within minutes by producing a recognizable taste when an active virus is present.

This rapid test, developed by researchers at the University of Würzburg (Würzburg, Germany), is based on a diagnostic principle that combines a sensor molecule (thymol, a natural flavor carrier) with a virus-specific recognition component so that active influenza viruses trigger release of the flavor in saliva. The method is flexible: flavor carrier and recognition component can be swapped (sweet, bitter, or salty flavors and alternative pathogen-specific building blocks), and the group envisions delivery formats such as chewing gum or lollipops that require no laboratory, electricity, or medical personnel.

In an experimental study, clinical samples were collected and documented by hospital teams while investigations on influenza virus particles were carried out in partner labs to validate the sensor concept. The proof-of-concept work, published in ACS Central Science, shows that contact between active influenza viruses and the neuraminidase-specific sensor releases the flavoring molecule, producing a clearly recognizable taste in infected mouths but not in uninfected controls. as.

The researchers are now working on incorporating the sensors into chewing gum or lollipops and adapting the system for mass production, a process they estimate will take about four years. They believe such low-threshold diagnostics would be particularly suitable for critical locations such as schools, nurseries, and retirement homes, and could be crucial in poorer countries for outbreak control. In the longer term, they envisage voluntary reporting via a smartphone app to map spread in real time and the use of artificial intelligence (AI) to predict where epidemics or pandemics might develop.

“Instead of relying on expensive and complicated testing procedures, we use the natural human sensory system – taste – as a tool for the early detection of infections,” said Professor Lorenz Meinel, who led the study. “This strategy opens up new possibilities for the early detection and control of influenza worldwide.”

Related Links:
University of Würzburg


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Syringes
Prefilled Saline Flush Syringes
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.